Changes in Hong Kong stocks | Gacos-B (01167) rose more than 8% in the afternoon, JAB-23E73 combined chemotherapy trial completed the first patient

Zhitongcaijing · 2d ago

The Zhitong Finance App learned that Gacos-B (01167) rose more than 8% in the afternoon. As of press release, it had risen 8.39% to HK$5.04, with a turnover of HK$14.1913 million.

According to the news, Gacos announced that a phase IB/III clinical trial of the company's pan-KRAS inhibitor jab-23E73 combined with albumin-binding paclitaxel and gemcitabine for first-line treatment of KRAS mutant pancreatic cancer has completed the first patient administration in China.

According to public information, JAB-23E73 is an oral pan-KRAS inhibitor independently developed by Gacos. The company grants AstraZeneca the exclusive licensing rights for this drug worldwide (except China). As far as mainland China is concerned, the two parties carry out joint development and joint commercialization cooperation. KRAS mutations occur extremely frequently in pancreatic cancer. The official launch of this research is an important milestone in the JAB-23E73 development process.